Incannex Healthcare wins award for innovative drug IHL-42X treating obstructive sleep apnea.

Incannex Healthcare has been recognized by MedTech Breakthrough with the "Best New Technology Solution for Drug Development" award for its lead drug candidate IHL-42X, an oral combination therapy for obstructive sleep apnea (OSA). IHL-42X combines dronabinol and acetazolamide, showing significant improvements in sleep quality and reduced daytime fatigue in Phase 2 trials. This award highlights Incannex's innovative approach to developing combination medicines targeting chronic conditions with limited treatment options. The company is also advancing therapies for rheumatoid arthritis and generalized anxiety disorder, aiming to improve patient outcomes with novel pharmacologic solutions.